Peter D. Kies's most recent trade in Inovio Pharmaceuticals Inc was a trade of 31,950 Common Stock Option done . Disclosure was reported to the exchange on May 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 31,950 | 31,950 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 26,100 | 26,100 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 4,771 | 4,771 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 4,771 | 32,823 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.95 per share. | 15 May 2025 | 2,566 | 30,257 (0%) | 0% | 2.0 | 5,004 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 39,050 | 39,050 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 31,900 | 31,900 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,010 | 10,019 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,010 | 31,012 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 3,997 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 3,997 | 28,364 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 26 Feb 2025 | 2,960 | 28,052 (0%) | 0% | 2.0 | 5,861 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 26 Feb 2025 | 2,362 | 26,002 (0%) | 0% | 2.0 | 4,677 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 4,771 | 26,929 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 4,771 | 9,542 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.07 per share. | 15 May 2024 | 2,562 | 24,367 (0%) | 0% | 13.1 | 33,485 | Common Stock |
| Inovio Pharmaceuticals Inc | D. Kies Peter | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 18,750 | 18,750 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Kies D. Peter | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 15,029 | 15,029 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | D. Kies Peter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,997 | 24,516 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 3,997 | 3,997 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Kies D. Peter | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.16 per share. | 26 Feb 2024 | 2,358 | 22,158 (0%) | 0% | 8.2 | 19,241 | Common Stock |
| Inovio Pharmaceuticals Inc | Kies D. Peter | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 1,878 | 21,627 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 1,878 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | D. Peter Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.16 per share. | 26 Feb 2024 | 1,108 | 20,519 (0%) | 0% | 8.2 | 9,041 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 171,756 | 171,756 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2023 | 59,737 | 268,409 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2023 | 59,737 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 11 Mar 2023 | 31,410 | 236,999 (0%) | 0% | 1.1 | 35,493 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2023 | 225,000 | 225,000 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2023 | 47,967 | 95,933 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2023 | 47,967 | 236,867 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.28 per share. | 26 Feb 2023 | 28,195 | 208,672 (0%) | 0% | 1.3 | 36,090 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2023 | 22,544 | 22,544 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2023 | 22,544 | 201,828 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.28 per share. | 26 Feb 2023 | 12,928 | 188,900 (0%) | 0% | 1.3 | 16,548 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2022 | 59,737 | 210,694 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2022 | 59,737 | 59,737 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.22 per share. | 11 Mar 2022 | 31,410 | 179,284 (0%) | 0% | 3.2 | 101,140 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2022 | 21,466 | 162,244 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2022 | 21,466 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.26 per share. | 08 Mar 2022 | 11,287 | 150,957 (0%) | 0% | 3.3 | 36,796 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2022 | 192,800 | 192,800 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2022 | 143,900 | 143,900 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2022 | 22,545 | 45,088 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2022 | 22,545 | 153,333 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.22 per share. | 26 Feb 2022 | 12,555 | 140,778 (0%) | 0% | 3.2 | 40,427 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Sale of securities on an exchange or to another person at price $ 10.01 per share. | 09 Jun 2021 | 33,750 | 130,788 (0%) | 0% | 10.0 | 337,838 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2021 | 13,750 | 20,000 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.16 per share. | 09 Jun 2021 | 13,750 | 164,538 (0%) | 0% | 2.2 | 29,700 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Sale of securities on an exchange or to another person at price $ 8.03 per share. | 03 Jun 2021 | 10,000 | 150,788 (0%) | 0% | 8.0 | 80,300 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Sale of securities on an exchange or to another person at price $ 8.52 per share. | 21 Apr 2021 | 10,000 | 160,788 (0%) | 0% | 8.5 | 85,200 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 59,737 | 119,474 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 59,737 | 202,198 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.57 per share. | 11 Mar 2021 | 31,410 | 170,788 (0%) | 0% | 10.6 | 332,004 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2021 | 27,566 | 146,856 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2021 | 27,566 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2021 | 21,467 | 153,749 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2021 | 21,467 | 21,466 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.19 per share. | 05 Mar 2021 | 14,574 | 132,282 (0%) | 0% | 9.2 | 133,935 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.91 per share. | 05 Mar 2021 | 11,288 | 142,461 (0%) | 0% | 8.9 | 100,576 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 104,833 | 104,833 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 67,633 | 67,633 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 15 Jan 2021 | 30,000 | 119,290 (0%) | 0% | 10.0 | 300,558 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 30,000 | 0 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.56 per share. | 15 Jan 2021 | 30,000 | 149,290 (0%) | 0% | 4.6 | 136,800 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Sale of securities on an exchange or to another person at price $ 10.69 per share. | 15 Dec 2020 | 20,000 | 119,290 (0%) | 0% | 10.7 | 213,706 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.16 per share. | 15 Dec 2020 | 11,250 | 139,290 (0%) | 0% | 2.2 | 24,300 | Common Stock |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 11,250 | 33,750 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 8,750 | 0 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Peter D. Kies | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 15 Dec 2020 | 8,750 | 128,040 (0%) | 0% | 2.4 | 21,000 | Common Stock |